Reference:
South African National Department of Health. (2022). Rapid review report for COVID-19 vaccine 5–11-year-old children: Should the BNT162b2 COVID-19 vaccine be used for children aged 5 -11 years old in South Africa.
Summary:
A rapid review evaluated the efficacy and safety of the BNT162b2 COVID-19 vaccine for children aged 5-11 in South Africa. The review identified one randomised trial and eleven observational studies. Results indicated that the vaccine significantly reduced COVID-19 infection risk by 91% compared to placebo. Additionally, it potentially lowered hospitalisation rates (64% reduction) but demonstrated little effect on mortality. Serious adverse events were rare, occurring equally in the vaccine and placebo groups. The review recommended vaccination for high-risk children, while suggesting that general vaccination for the wider population may not be justified due to limited benefits and logistical challenges. The paediatric formulation is still not registered in South Africa, and the cost remains unknown. Updates to the review will follow any new evidence or registration of the vaccine.